tigations were made;

(b) whether any meeting took place on 14-3-1989 in the chamber of C&MD between the employees and other officials;

(c) if so, what are the details thereof; and

(d) the details of the letters dated 1-6-89, 22-6-89 and 11-7-89 respectively, issued by the Senior Personnel Manager in this regard?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) to (c) The IDPL management has reported that as per records of the company, the then Director (Marketing) of IDPL had made no charges against the said former Marketing Executive. According to IDPL, there is no record of any such meeting.

(d) The IDPL management had through three letters dated 1-6-89, 22-6-89 and 11-7-89 informed the said former Marketing Executive that no leave was being sanctioned to him and he was advised to report for duty.

BICP Report on Drug Prices

464. SHRIMATI SATYA BAHIN: Will the PRIME MINISTER be pleased to state:

(a) what are the names of bulk drugs in respect of which BICP have not sent their report on the fair prices after the announcement of DPCO, 1987;

(b) what are the prices of such bulk drugs on which the prices of major formulations are based;

(c) whether it is a fact that the producers of the bulk drugs and their formulations falling in such category are making profits at the cost of common man; and

(d) what steps have been taken to rectify the situation?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) Out of total bulk drugs under price control listed in Schedule-I & II of DPCO, 1987, BICP has submitted their recommendations in respect of 81 bulk drugs. Out of the balance, 47 bulk drugs are those which are either not manufactured in the country or are being substantially imported. The names of these 47 bulk drugs are given in the Statement-I. (*See* below). For the remaining 15 bulk drugs, the BICP has issued questionaire to the concerned manufacturers and replies are awaited. The names of these drugs are given in Statement-II.

(b) For the purpose of price fixation of formulations based on bulk drugs for which BICP has not conducted their cost-cum-technical study, the Sub-Committees of the Drugs Price Review Committee adopts weighted average landed cost of imported bulk drugs furnished by the Director General of Health Services, except in case of bulk drugs Amoxycillin, Ampicillin & Doxycycillin for which Government fixes the prices on the basis of the cost data available with it.

(c) This has not come to the notice of the Government.

(d) Does not arise.

Statement-I

SCHEDULE I

S.No.	Bulk Drug
1.	Atropine
2.	Iodoxouridine
3.	Homatropin
4.	Pyremithamine
5.	Sulphamethopyrazine

SCHEDULE II

6.	Cyproheptadine
7.	Carbamazepine
8.	Calcium Peutothenate
9.	Dipyridamole
10.	Ergometrine
11.	Griseofulvin
12.	Iron Dextran
13.	Isosorbide Dinitrate
14.	Ketoprofen
15.	Loperamide
16.	Oxythazine
17.	Pentazocine
18.	Piperazine
19.	Sulphamethizole
20.	Salazosulphapyrazine
21.	Sulphadoxine
22.	Triamterene
23.	Verapamil
24.	Neomycin

25. Thioridazine
26. Amtryptyline
27. Trifluperazine
28. Trimipramine
29. Triprolidine
30. Polymixin B. Sulphate
31. Glipizide
32. Pyrithyldione
33. Zinc Bacitracin
34. Mitomycin
35. Tolnefatate
36. Fluocinoloxe Acetoxide
37. Carbenicillin Sodium
38. Oxyfedrine Hcl
39. Hysoline N Butyl Bromide
40. Triamlinolone
41. Naproxen
42. Pyrithioxine
43. L-Dopa
44. Norgesterol
45. Ethistarone
46. Carbenixolone
47. Reserpine.

Statement-II

S.No. Name of Bulk Drug

1. Cemetidine
2. Ranitidine
3. Amoxycillin
4. Ampicillin
5. Dexycycilline
6. Diphenoxylate
7. Hydralazine
8. Metoclopracide
9. Malidixic Acid
10. Promethazine
11. Timolol
12. Metroprolol
13. Chlorpromazine
14. Imiphamine
15. Povidone Iodine

Profitability of Drug Companies

465. SHRI RAJNI RANJAN SAHU:
SHRI ANANT RAM JAISWAL:
Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that Government are monitoring the profitability of drug companies;

(b) if so, what was the profitability both before tax and after tax of each of twenty five major drug companies during the last three years, year-wise;

(c) what was the total import of raw materials and bulk drugs during the above period;

(d) what are the names of new bulk drugs for which production was started by each of these companies during his last three years and what was the production of each, year-wise from commencement of production; and

(e) what are the names of medicines for which any of these companies reduced prices during the above period?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) and (b) Information as available of profit before tax of twenty five major drug companies is at Statement. (*See* below)

(c) Company-wise imports are not monitored by the Government.

(d) To the extent information is available the details in regard to industrial Licenses granted for the production of new bulk drugs during last 3 years are as follows:

S. No.	Name of the Company	Name of New Bulk Drug	Date of issue of Industrial License	Capacity	Production
1	2	3	4	5	6
1.	E. Merck	Guaiazolene Crystals	6/91	10 Tonnes	Not yet Reported